| UCB S.A. UNSP.ADR 1/2 |
| USA |
| Gesundheit |
| US9034801012 / A14WZY |
| UNC0 (Frankfurt) |
| FRA:UNC0, ETR:UNC0, UNC0:GR |
| - |
| https://www.ucb.com/ |
|
UCB S.A. is an innovative global biopharmaceutical company based in Belgium, known for its focus on developing therapies for severe diseases in immunology and neurology. UCB aims to provide high-impact solutions for conditions affecting millions worl..
>Volltext.. |
| 49667.41 Mio. EUR |
| 49441.11 Mio. EUR |
| 7510.16 Mio. EUR |
| 2567.19 Mio. EUR |
| 1525.93 Mio. EUR |
| 4.01 EUR |
| 2257.96 Mio. EUR |
| 2263.99 Mio. EUR |
| 2160.3 Mio. EUR |
| 0.56 |
| 31.78% |
| 54.6% |
| 0.68 EUR |
| 0.32% |
| 0.32% |
| 28.04.25 - 0.6781829€ 26.04.24 - 0.6246308€ >weitere anzeigen... |
| - |
| UCB ADR, UCB |
| 08.04.26 |
|
||||
|
||||
|
||||
|
||||
|